In 2018, Q&M established a company, EM2AI, to work on artificial intelligence (AI) projects that target pain points such as this. EM2AI is now preparing for clinical trials to get approval from the Health Sciences Authority for its AI platform, under the Class B medical device category. The new AI platform is meant to reduce the chance of misdiagnoses, and recommend treatment plans in a more objective and transparent way.

Once approved, EM2AI’s product will be rolled out at Q&M’s clinics before being sold to others. “The monetisation part, we are not worried. We want to get the job done properly first to ensure that we are giving good advice based on this AI for the benefit of our patients,” said Dr Ng Chin Siau, Chief Executive of Q&M Dental Group.

Q&M is now also looking into investing in startups, especially in the fields of AI and medtech. Raymond Ang, chief operating officer of Q&M, said startups in the proof-of-concept or production stage have been approaching the company.

Read more about Q&M’s AI and tech investments plans on The Business Times.